References
- Ebadi M, Srinivasan SK. Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 1995; 47(4)575–604
- Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23(4)637–51
- Kasper S. First-episode schizophrenia: The importance of early intervention and subjective tolerability. J Clin Psychiatry 1999; 60(suppl 23)5–9
- Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14(1)47–57
- Buckley PF. Treatment of schizophrenia: let‘s talk dollars and sense. Am J Managed Care 1998; 4: 369–83
- Davies JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 533–64
- Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002; 16(7)473–84
- Leucht S, Barnes T R, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160(7)1209–22
- National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. No. 43, NICE, London, 2002
- Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426–33
- Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290–9
- Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18(2)113–32
- Paton C, Okocha C. Risperidone long-acting injection: The first 50 patients. Psychiatr Bull 2004; 28(1)12–14
- Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6 month follow-up of 100 patients. J Clin Psychiatry 2004; 65(8)1076–83
- Kane JM, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125–32
- Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–96
- Patel MX, Young C, Samele C, Taylor DM, David AS. Prognostic indicators for early discontinuation of risperidone long-acting injection. Int Clin Psychopharmacol 2004; 19(4)233–9
- Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychoparmacol 2000; 14(4)409–18